Fig. 4

The COL1A1-specific agents entering clinical trials and their targets. COL1A1 collagen I, Egr-1 early growth response-1, IFNγ Interferon-γ, IGFBP-1 insulin-like growth factor binding protein 1, IL-1β Interleukin (IL)-1 beta, MMP2 matrix metalloproteinase 2, NF-κB Nuclear factor κB, p-eIF2α phosphorylated eIF2α, PRL-1 phosphatase of regenerating liver-1, SMAD3 mothers against decapentaplegic homolog 1, TNF-α tumor necrosis factor alpha, WT1 Wilms’ tumor gene 1, DMD duchenne muscular dystrophy